These data indicated that in addition to treat relapsed or refractory FLT3-positive AML, gilteritinib could also function as drug repositioning, that is, treating for ALK-positive NSCLC including lorlatinib-resistant ALK I1171N/F1174I double mutant. The gene discussed is ALK; the disease is non-small cell lung carcinoma.